Short Sellers Dig In as Valneva’s Halbjahreszahlen Approach a Defining Moment
Published on 07/25/2026 at 01:41 | Redaktion boerse-global.de
The French-Austrian vaccine developer Valneva finds itself in an increasingly precarious position as its shares sink to fresh lows and hedge funds pile on bets against the stock. With the company set to release first-half results on August 13, the coming weeks will test whether management can bridge the yawning gap between clinical promise and market reality.
The stock touched a new 52-week trough of €2.03 on Friday before closing at €2.09, down 0.95 percent on the day. That leaves the shares nearly 60 percent below the €5.16 peak reached in August 2025. The decline has been relentless: the stock has shed 43.71 percent since the start of the year, with a weekly loss of 2.97 percent and a monthly drop of 9.67 percent. The relative strength index now stands at 32, a level that typically signals oversold conditions — though technical indicators alone offer little comfort given the fundamental headwinds.
Hedge Funds Circle Ahead of Key Data
The most telling sign of institutional skepticism is the buildup in short positions. As of July 22, net short interest in Valneva stood at 4.31 percent of issued share capital, with U.S. hedge fund D.E. Shaw & Co. steadily increasing its bearish wager through the summer months. The timing is notable: short sellers are positioning themselves just as Valneva approaches a series of operational milestones that could either vindicate or undermine their thesis.
The first-quarter numbers already painted a grim picture. Revenue collapsed 37.2 percent to €30.9 million, a drop that management attributes to the planned wind-down of the third-party distribution business — a strategic shift toward higher-margin proprietary products that is exacting a painful short-term toll on the top line. The company also withdrew its U.S. application for the Chikungunya vaccine IXCHIQ in January after the FDA flagged safety concerns, forcing a recalibration of near-term revenue expectations and a downward revision to the full-year 2026 outlook.
Should investors sell immediately? Or is it worth buying Valneva?
Capital Raised, But Confidence Remains Fragile
Valneva moved to shore up its balance sheet in April, raising roughly €84 million in a capital increase led by Frazier Life Sciences and other healthcare-focused investors. The fresh funds are earmarked to support pipeline development and commercial expansion of established products, meaning liquidity should not be an immediate concern regardless of what the August report shows. That capital cushion, however, has done little to restore confidence in the stock.
The analyst community remains surprisingly constructive given the price action. Six of seven analysts covering the stock rate it a buy, with a consensus price target of €5.23 — more than double the current level. The most recent individual target stands at €5.60. Only one analyst recommends selling. The disconnect between Street optimism and the market’s verdict is stark, and it underscores just how much hinges on the upcoming numbers.
Pipeline Progress Offers a Counter-Narrative
Valneva’s longer-term story rests on two late-stage programs. The Lyme disease vaccine candidate VLA15, developed in partnership with Pfizer, generated strong phase 3 efficacy data in March under the VALOR study. What remains unclear is the timeline for regulatory filings in the U.S. and Europe — a question that the August 13 webcast may help answer. The company is also advancing its Shigellosis vaccine program, while its commercial portfolio continues to generate revenue from three established travel vaccines.
Valneva at a turning point? This analysis reveals what investors need to know now.
The fundamental tension is plain: clinical progress has not translated into commercial momentum or share price support. The short sellers are betting that the revenue recovery will take longer than the market expects, and that the gap between pipeline value and near-term earnings power will persist. For Valneva, the H1 report represents a chance to demonstrate that the first-quarter revenue slump was a one-off adjustment rather than the start of a deeper erosion. If management can show that the distribution restructuring is nearing completion and that core product sales are stabilizing, the current valuation — with the stock trading at a fraction of the average analyst target — could begin to look compelling. If not, the shorts may have the upper hand for some time yet.
Ad
Valneva Stock: New Analysis - 25 July
Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
